Rectal Indomethacin Doesn't Prevent Post-ERCP Pancreatitis

This article originally appeared here.
Share this content:
Rectal Indomethacin Doesn't Prevent Post-ERCP Pancreatitis
Rectal Indomethacin Doesn't Prevent Post-ERCP Pancreatitis

THURSDAY, April 7, 2016 (HealthDay News) -- For patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), rectal indomethacin does not prevent the development of post-ERCP pancreatitis (PEP), according to a study published in the April issue of Gastroenterology.

John M. Levenick, M.D., from the Penn State Hershey Medical Center, and colleagues conducted a prospective trial of 449 patients undergoing ERCP (about 70 percent at average risk for PEP). Patients were randomized to a single dose of rectal indomethacin or a placebo suppository (223 and 226 patients, respectively). Patients were followed for the primary outcome of the development of PEP.

The researchers found that 7.2 and 4.9 percent of patients in the indomethacin and placebo groups, respectively, developed PEP (P = 0.33). Between the groups, complications and the severity of PEP were similar. The study was stopped early owing to futility per a priori protocol guidelines.

"In a randomized controlled study of consecutive patients undergoing ERCP, rectal indomethacin did not prevent post-ERCP pancreatitis," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »